| Name | Title | Contact Details |
|---|
Clover Health is a data driven health insurance startup driving to improve the overall state of healthcare in America. We are hiring software engineers, data scientists, designers and product folks who can help us understand our members` wellness and steer them clear of any health risks down the road. Unlike other health insurance companies also embracing preventive health, Clover`s Medicare is built on technology from the ground-up. Integrating our systems with doctors, clinicians, and nurse practitioners, Clover`s data team helps healthcare professionals in the field intervene directly into patients` wellness to help them avoid acute health episodes. If you`re a passionate person and interested in changing healthcare for the better, then Clover may just be the place for you.
Recent changes in Medicare coding requirements have caused hospitals to suffer from lost revenues, penalties and forfeiture of reimbursements due to inadequate documentation. Founder Dr. Jon Elion, who earlier created the highly successful Heartlab imaging software, tackled this problem with an expert team. The result was the company`s premiere product, ChartWise:CDI, which is the first-to-market Computer-Assisted Clinical Documentation Improvement (CACDI) software system designed to improve precision in quality clinical documentation to support revenue assurance. In February 2014 ChartWise launched an upgraded system, ChartWise 2.0—redefining CDI with powerful new features and an advance new user interface. The program is easy for medical professionals to understand and use, has a light IT footprint, and offers hospitals a way to mitigate risk, maximize reimbursement, and gain insight into their medical documentation improvement efforts. No other program is as robust, or addresses the clinical documentation challenges, the way ChartWise 2.0 does.
Marquette General Health System is a Marquette, MI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AcelRx Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. The Company`s product candidates, DSUVIA™ (known as ARX-04 outside of the United States) and ZALVISO®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. DSUVIA is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. The Phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. In clinical studies, DSUVIA demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and vomiting. A New Drug Application (NDA) was filed with the FDA in December 2016. ZALVISO is designed to deliver sublingual tablets containing 15 mcg sufentanil via a novel hand-held, pre-programmed, patient-controlled analgesia system. Three Phase 3 clinical trials have been completed in patients who had undergone major abdominal or orthopedic surgeries. A fourth study (IAP312) is underway to further evaluate the overall performance of the ZALVISO System in post-surgical patients. ZALVISO is currently approved by the European Commission for the management of acute moderate-to-severe post-operative pain in adult patients in a hospital setting, and is marketed by Grünenthal Group, AcelRx`s licensee in Europe and Australia. In the United States and other geographies, ZALVISO remains an investigational product.
American Public Health Association is a Washington, DC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.